TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Transplantation for Primary Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, ≥18 years with primary C. difficile infection, defined by the following three criteria:~  1. Diarrhea as defined by the WHO (≥3 loose stools per day), and~ 2. Positive stool test for toxin producing C. difficile, and~ 3. No evidence of previous C. difficile infection during 365 days before enrolment.~* Written informed consent~Exclusion Criteria:~* Known presence of other stool pathogens known to cause diarrhea.~* Ongoing antibiotic treatment for other infections that cannot be stopped before study treatment administration.~* Inflammatory bowel disease or microscopic colitis.~* \&lt; 3 months life expectancy.~* Serious immunodeficiency, defined as one of the following:~  * Ongoing or recent chemotherapy and current or expected neutropenia with neutrophil count of \&lt; 500/μL.~ * Active severe immunocompromising disease.~* Inability to comply with protocol requirements.~* Need of intensive care.~* Known irritable bowel syndrome, diarrheal type.~* Pregnancy or nursing.~* Known or suspected toxic megacolon or ileus.~* Total or subtotal colectomy, ileostomy or colonostomy.~* Contraindications for rectal catheter insertion~* Known hypersensitivity or other contraindications to vancomycin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fecal microbiota transplantation (Type: EXPERIMENTAL): Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment.
- Antibiotic treatment (Type: ACTIVE_COMPARATOR): Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Weight Loss and Alcohol Perception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese, with body weight less than 450 lbs~* non-smoking female volunteers of any race~* age 30-55 years~* drink alcohol in moderation and meet all of the BSC's indications and criteria for RYGB surgery. NIH/NIAAA criteria specify an average of between 3 and 7 standard drinks per week as moderate alcohol drinking (for women). In addition, included participants must fall within the upper or lower tercile of scores on the ASQ for a bariatric population, as determined by the investigator's previous studies with this population.9,10,19~Exclusion Criteria:~* their AUDIT scores (16 or above) indicate the possibility of a current or prior alcohol use disorder.~* they report typically drinking less than once per month and consuming less than 3-4 drinks per occasion.~* they are taking prescribed psychoactive medications, other than selective serotonin reuptake inhibitors (SSRIs) for anxiety/depression.~* they are taking medications that might interfere with alcohol metabolism (e.g., anti-histamine h2 receptor antagonists \[mainly, antacids used to treat GERD and gastro-intestinal ulcers\], certain antibiotics such as erythromycin, or other drugs influencing hepatic cytochrome P450 2E1; see medicine.iupui.edu/clinpharm/ddis/table.aspx).~* their medical records indicate current anemia.~* their FTND scores indicate moderate or greater nicotine dependence (4 or above).~* they report they are trying to become pregnant, or produce a positive urine screen for pregnancy at the lab session.~* their body weight is \> 450 lbs.~* they have participated in any other research study or medical procedure involving ionizing radiation exposure greater than a chest X-ray in the past 12 months.~* they live more than 60 miles from the CRC.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Alcohol: Oral administration (Type: EXPERIMENTAL): Participants in this arm will consume a measured dose of alcohol orally, with the goal of achieving a target peak breath alcohol concentration of .065% within 20 minutes.
- Alcohol: Intravenous administration (Type: EXPERIMENTAL): Participants in this arm will be infused intravenously with a dose of alcohol sufficient to raise their breath alcohol concentration to .065% within 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial on Endovascular Aneurysm Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least one documented subarachnoid aneurysm, never ruptured~* Patient aged 18 or older~* Life expectancy more than 10 years~Exclusion Criteria:~* Patients with recent (less than 3 months) intracranial haemorrhage~* Lesion characteristics unsuitable for endovascular treatment~* Patients with a single extradural aneurysm~* Aneurysms \< 3 mm or giant aneurysms (≥ 25 mm)~* Patients with a poor outcome (Rankin scale ≥ 3) after the rupture, surgical or endovascular treatment of another aneurysm~* Patients with incompletely treated aneurysms that have previously ruptured~* Patients with associated arteriovenous malformations~* Patients with new severe progressive symptoms in relationship with the aneurysm (sudden onset, severe persisting headaches suggestive of impending rupture, third-nerve palsy, mass-effect)~* Patients with previous intracranial haemorrhage from unknown etiology~* Patients with multiple unruptured aneurysms in whom surgical clipping of one or many aneurysms is planned in addition to endovascular management~* Patients with absolute contraindications to anaesthesia, endovascular treatment, or administration of contrast material, including low-osmolarity agents or gadolinium~* Pregnant patients~* Patients unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conservative (Type: NO_INTERVENTION): Conservative management (watchful observation)
- Endovascular (Type: ACTIVE_COMPARATOR): Endovascular treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluid Responseveness in Sepsis and Its Correlation to CVP

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. adult patients age≥18-year-old; written consent will be obtained.~2. septic shocked patients show signs of acute circulatory failure at any time within the first 72 hours.~Exclusion Criteria:~1. Patients confirmed to have cardiogenic shock.~2. History of heart failure or patient known to have moderate to severe valvular heart disease, congenital heart disease.~3. The presence of carotid artery stenosis \>50% , newly detected common carotid stenosis \>50% during the study period.~4. Non-sinus rhythm.~5. Moderate to severe anemia.~6. Markedly increased intraabdominal pressure as abdominal compartment syndrome, pregnancy.~7. Medically diseased kidneys, ureteric obstruction peri-nephric collection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx or cancer of unknown primary (CUP) in the neck in previously irradiated tissue, with former irradiation with curative intent.~* Patients with non-symptomatic distant metastases and local, regional or combined locoregional recurrence can be included.~* In case of non-metastatic disease, the recurrence must be primarily unresectable recurrence and/or patients refused surgery.~* Time interval 6-24 months after the end of the initial radio(chemo)therapy for primary head and neck cancer.~* Decision of the Head and Neck Tumor Boards at the recruiting centre to offer salvage radio(chemo)therapy, palliative chemotherapy or anti-PD-1 antibody treatment with nivolumab for cisplatin-refractory locoregional recurrent head and neck squamous cell carcinoma.~* Karnofsky performance status ≥ 70.~* Age ≥ 18 years old.~* Informed consent obtained, signed and dated before specific protocol procedures.~Exclusion Criteria:~* Previous radiotherapy was for cT1-2 cN0 M0 glottic cancer.~* Grade ≥ 4 late toxicity after the initial radio(chemo)therapy.~* Brachytherapy as treatment for second primary / recurrence.~* Previous (combination with) immunotherapy for the primary or the recurrent squamous cell carcinoma.~* Impossibility of oral intake of cyclophosphamide.~* For patients receiving cyclophosphamide: necessary intake during therapy of allopurinol, amiodarone, digoxin, hydrochlorothiazide, indomethacin, phenobarbital, phenytoin, warfarin. clopidogrel, ticlopidine, carbamazepine, efavirenz, rifampicin, ritonavir~* High risk for arterial blow-out: 1 of following criteria is sufficient to exclude patients:~  1. soft tissue necrosis~ 2. skin invasion of the recurrent cancer~ 3. circumferential involvement of \> 180° of a carotid artery~* Symptomatic distant metastases.~* Other uncontrolled second primary tumors.~* Pregnant or lactating women.~* Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.~* Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic body radiotherapy + IM (Type: EXPERIMENTAL): Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically- confirmed metastatic breast adenocarcinoma~* Age 18-75 years~* HER2 status positive according to the local institution reported grade 3+ staining intensity (on a scale of 0 to 3) by means of immunohistochemical analysis or grade 2+ staining intensity by means of immunohistochemical analysis with gene amplification on fluorescence in situ hybridization~* Previous therapies had to include, regimens containing an anthracycline and a taxane~* Previous treatment with trastuzumab, alone or in combination with chemotherapy for locally advanced or metastatic disease, is required~* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)~* Performance status (WHO) 0-2~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit; AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases); adequate renal function (serum creatinine \<1.5 times the upper normal limit); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function~* No radiation of measurable disease (except brain metastases)~* No progressive brain metastases according to clinical or radiological criteria~* No brain metastases without prior radiation therapy~* Written informed consent~Exclusion Criteria:~* Patient unable to take oral medication~* Active infection~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* Other invasive malignancy except nonmelanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Vinorelbine metronomic/Lapatinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Accuracy of Urinary NGAL in Predicting CardioRenal Syndrome in Acute Heart Failure at Emergency - CYNDERELA-HF Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* acute heart failure according to the Framingham's criteria~* informed consent signed~Exclusion Criteria:~* Acute coronary syndrome~* cardiogenic shock~* terminal renal disease~* transplanted patients~* known nephrotoxicity exposure~* urinary tract infection~* sepsis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute Heart Failure (Type: None): Patients admitted to emergency room in Acute Heart Failure at Hospital PróCardíaco and Hospital Universitario Antonio Pedro

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improved Patient Safety for Acute Restless Medical Patients With Supplemental Observation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 65 years of age with a CAM score of 2 or higher.~Exclusion Criteria:~* paranoia~* severe dementia~* suicidal~* need for permanent guard

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Camera observation (Type: ACTIVE_COMPARATOR): Camera observation
- No camera observation (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Primary FSGS diagnosed by renal biopsy.~2. Urine protein creatinine ratio (UPCR) ≥2.0 mg/mg, serum albumin ≤3.2 g/dL and can be immunosuppressant treatment-naïve, or receiving treatment with steroids.~3. Stable proteinuria, renal function, and BP.~Exclusion Criteria:~1. Clinical or histologic evidence of secondary FSGS.~2. Histologic evidence of collapsing variant FSGS.~3. eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of ≤30 mL/minute/1.73 m2 at initial screening assessment or ≤45 mL/minute/1.73 m2 at last qualifying assessment.~4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.~5. Current or medical history of:~   * Congenital or acquired immunodeficiency.~  * In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.~  * Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.~  * Current or past lymphoproliferative disease or previous total lymphoid irradiation.~  * Severe viral infection within 3 months of screening, or known HIV infection. Severe viral infection is defined as active disease requiring antiviral therapy.~  * Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Voclosporin (Type: EXPERIMENTAL): Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who previously received allogeneic hematopoietic cell transplantation due to hematologic malignancy, bone marrow failure syndrome, and other compatible disease.~* Patients who are diagnosed as bronchiolitis obliterans (BO) according to the NIH diagnostic guideline which is suggested as below.~* Patients should be 15 years of age or older, but younger than 75 years.~* Patients should have estimated life expectancy of more than 3 months.~* Patients must have adequate hepatic function (bilirubin less than 3.0 ㎎/㎗, AST and ALT less than three times the upper normal limit).~* Patients must have adequate renal function (creatinine less than 2.0 ㎎/㎗).~Exclusion Criteria:~* Presence of significant active infection~* Presence of uncontrolled bleeding~* Any coexisting major illness or organ failure~* Patients with a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.~* Nursing women, pregnant women, women of childbearing potential who do not want adequate contraception~* Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years following therapy with curative intent (except curatively treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Reduction in Symptomatic Esophageal Stricture Formation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed Barretts mucosa with high grade dysplasia or early esophageal adenocarcinoma (T1a, intramucosal adenocarcinoma).~2. Barretts segment ≥ 30% circumference, ≤C3 and ≤M5.~3. The general health condition of the patient permits anesthesia for endoscopy.~4. Patient is 18 years of age or older.~5. Informed consent is obtained~Exclusion Criteria:~1. Previous (referral) biopsies show low grade dysplasia only, or invasive adenocarcinoma.~2. Barretts segment \<30% circumference, \>C3 or \>M5.~3. During initial gastroscopy there are highly suspicious areas for submucosal invasive cancer (Kudo pit pattern type V; excavated/depressed type morphology; large smooth or ulcerated nodule). In cases of significant doubt, initial resection is of the highly suspicious area only, and urgent histology processing requested. If submucosal invasion is excluded, the patient is rebooked for 1st stage complete barrett's excision (60% circumferential resection) and randomization after a 4-6 weeks interval.~4. Presence of a tight peptic oesophageal stricture that impedes safe and effective endoscopic mucosal resection using a cap (Cook Medical).~5. Active malignancy, uncontrolled Diabetes Mellitus, active or untreated major psychiatric disorder, uncontrolled infection, uncontrolled hypertension, uncontrolled or severe congestive cardiac failure, non-correctable coagulopathy (INR\>2, or platelet count \<60 x 109/L), osteoporosis, recent peptic ulcer disease, moderate-to-severe glaucoma or untreated glaucoma, or pregnancy.~6. Unable to provide informed consent~7. Allergy to compound used in tablet formulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- prednisone (Type: EXPERIMENTAL): Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.
- placebo (Type: PLACEBO_COMPARATOR): Placebo tablets will be taken in the same manner as the prednisone arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues